Trial Profile
Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody Durvalumab in Combination With Paclitaxel in Patients With Metastatic Triple Negative PD-L1 Positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 02 Jul 2020 Status changed from active, no longer recruiting to completed.
- 21 Oct 2019 Planned number of patients changed from 34 to 25.
- 21 Oct 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.